Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN(a)-PreEvent: Olpasiran for primary prevention of major cardiovascular events in adults with elevated lipoprotein(a)
CTR20263091Phase 3Active
- Sponsor
- Amgen
- Start
- Aug 2025
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of olpasiran in atherosclerotic disease, None, lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Amgen. Started Aug 2025; status: active.
02
Drugs
olpasiran
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on CTR20263091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263091.